⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7292397 | 0.68 | — | — | |
| SCHEMBL10763563 | 0.68 | — | — | |
| SCHEMBL196004 | 0.67 | — | — | |
| SCHEMBL7106992 | 0.66 | — | — | |
| SCHEMBL10745821 | 0.66 | — | — | |
| SCHEMBL6371601 | 0.66 | — | — | |
| SCHEMBL9777662 | 0.65 | — | — | |
| SCHEMBL5491548 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL29551060 | 0.60 | — | — | |
| SCHEMBL11190421 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381208-A1 | CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON’S DISEASE | H. LUNDBECK A/S (DK) | 2025-12-18 | — | — | US | disclosed |
| US-12398169-B2 | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid | H. LUNDBECK A/S (DK) | 2025-08-26 | — | — | US | disclosed |
| US-12319710-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's diseases | H. LUNDBECK A/S (DK) | 2025-06-03 | — | — | US | disclosed |
| US-12226428-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | H. LUNDBECK A/S (DK) | 2025-02-18 | — | — | US | disclosed |
| US-20240352055-A1 | PROCESS FOR THE MANUFACTURE OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | US | disclosed |
| US-20240025857-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2024-01-25 | — | — | US | disclosed |
| US-11851456-B2 | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| US-11707476-B2 | Catecholamine prodrugs for use in the treatment of parkinson's disease | H. LUNDBECK A/S (DK) | 2023-07-25 | — | — | US | disclosed |
| US-20220257623-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2022-08-18 | — | — | US | disclosed |
| US-20220213136-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASES | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| US-20220194978-A1 | PROCESS FOR THE MANUFACTURE OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | US | disclosed |
| EP-2400967-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. Lundbeck A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097092-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. LUNDBECK A/S (DK) | 2010-09-02 | — | — | WO | disclosed |